Follicular large cell lymphomas, also known as FLCL, are a category of non-Hodgkin lymphomas (NHL) that primarily impact the lymphatic system. These lymphomas originate from abnormal B cells in the lymph nodes and can spread to other organs over time.
Follicular large cell lymphomas are characterized by the presence of large, atypical cells within the lymph nodes, known as centroblasts. These abnormal cells disrupt the normal functioning of the lymphatic system by causing the formation of tumor-like masses or nodules in various parts of the body.
The exact cause of follicular large cell lymphomas is currently unknown, but certain genetic mutations and chromosomal abnormalities have been observed in some cases. Risk factors for developing this condition include age (most commonly affects adults over 40) and a weakened immune system.
Symptoms of follicular large cell lymphomas may include painless swelling of lymph nodes, fatigue, fever, night sweats, weight loss, and general malaise. Diagnosis often involves a combination of physical examination, blood tests, biopsies, imaging tests, and lymph node sampling.
Treatment options for follicular large cell lymphomas depend on the extent of the disease and may vary from person to person. Common approaches include watchful waiting for asymptomatic cases, chemotherapy, targeted therapy, immunotherapy, radiation therapy, and stem cell transplantation. The overall prognosis for this type of lymphoma varies, with some individuals responding well to treatment and achieving long-term remission, while others may experience disease progression or recurrence. Regular follow-up and monitoring are essential to detect any changes and ensure timely intervention.
